Yahoo Finance is in Davos! Get the latest updates here

MannKind Corporation (MNKD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

4.1770

+0.1770

(+4.43%)

As of 03:04PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Fast Stochastic

View all chart patterns

Performance Outlook

Previous Close	4.0000
Open	4.0000
Bid	4.1200 x 2900
Ask	4.1300 x 2200
Day's Range	3.9200 - 4.1850
52 Week Range	2.4900 - 5.5300
Volume	5,730,578
Avg. Volume	4,015,462

Market Cap	1.055B
Beta (5Y Monthly)	1.95
PE Ratio (TTM)	N/A
EPS (TTM)	-0.3750
Earnings Date	Aug 09, 2022 - Aug 15, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	6.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MNKD

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

MannKind Corporation
Technical Assessment: Neutral in the Intermediate-TermWe are raising our intermediate-term technical outlook to neutral from bearish. This reverses our April 22 intermediate-term downgrade from neutral to bearish. This action is not a green light and we are not saying the bottom is in and it's up, up, and away from here. But we do think the major indices are attempting to hammer out (via a candlestick pattern) a bottom because we have seen a few "sticks" in recent trading sessions. Simply put, we are seeing days where stocks trade significantly lower but then finish strong.
Rating
Fair Value
Economic Moat
12 hours agoArgus Research

All

Zacks
United Therapeutics (UTHR) Gains on Tyvaso DPI Approval
The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.
- United Therapeutics Announces FDA Approval of Tyvaso DPI™
  Business Wire
- United Therapeutics gets long-awaited FDA approval as competitor Liquidia takes stock hit
  American City Business Journals
GlobeNewswire
MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
MannKind celebrates that the FDA has approved United Therapeutics’ Tyvaso DPI™ (treprostinil) inhalation powder Tyvaso DPI™ production is underway at MannKind Corporation (Nasdaq: MNKD) in Danbury, Conn. On May 24, 2022, MannKind celebrated that the U.S. Food and Drug Administration (FDA) has approved United Therapeutics’ Tyvaso DPI™ (treprostinil) inhalation powder. Tyvaso DPI represents the second FDA-approved product utilizing MannKind’s innovative Technosphere® inhalation technology. MannKin
GlobeNewswire
MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will ring the opening bell at the Nasdaq stock exchange on Monday, May 23, 2022 at 9:30 am ET at the Nasdaq MarketSite at Times Square. The ceremony will begin at a